[Market Focus] TiumBio Soars on Phase 2 Clinical Efficacy Results

As of 9:15 a.m. on May 7, 2025, shares of TiumBio were trading at 6,090 won on the KOSDAQ market, up 18.25% from the previous session's closing price. This appears to be due to the announcement of Phase 2 clinical trial results regarding the efficacy of its uterine fibroid treatment.

TiumBio announced that its partner company, Daewon Pharmaceutical, had successfully achieved the primary endpoint of 'reduction in heavy menstrual bleeding' in a Phase 2 clinical trial for 'Merigolix (TU2670)' as a treatment for uterine fibroids. According to the company, the trial results demonstrated statistically significant improvement across all dosage groups compared to placebo. The company also added that all secondary endpoints, including reduction in fibroid size, increase in hemoglobin levels (improvement in anemia), and reduction in pain, showed clear improvement compared to placebo.

Merigolix, a gonadotropin-releasing hormone (GnRH) antagonist, can be administered orally, unlike existing injectable treatments, providing patients with a relatively convenient and less burdensome treatment option.

According to market research firm Global Market Insights, the global uterine fibroid treatment market is expected to grow from 2.5 trillion won in 2022 to 6.6 trillion won in 2032, with an average annual growth rate of about 10%.

Merigolix is a novel drug candidate that can be used for various female hormone-related conditions, including endometriosis, uterine fibroids, assisted reproductive technology (ART), and precocious puberty. The company explained that it had already demonstrated therapeutic efficacy and safety in a previous Phase 2 clinical trial for endometriosis in Europe.